Cited 16 times in
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장종희 | - |
dc.date.accessioned | 2020-02-26T06:53:31Z | - |
dc.date.available | 2020-02-26T06:53:31Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 0167-594X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/175329 | - |
dc.description.abstract | BACKGROUND: Tumor treating fields (TTFields) are anti-mitotic, non-invasive loco-regional cancer therapy comprising low intensity, intermediate frequency alternating electric fields. TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We report on Korean newly diagnosed GBM patients who participated in the EF-14 trial. METHODS: Thirty-nine participants of the EF-14 trial were enrolled at 8 sites in South Korea. Patients (24 TTFields/TMZ; 14 TMZ alone) received: TTFields (200 kHz) for > 18 h/day; TMZ at 120-150 mg for 5 days per a 28 day cycle. Safety and efficacy were assessed. RESULTS: Patient baseline characteristics were balanced in the 2 arms and the mean age was 52.1 years, 66.7% were male with a mean KPS of 90. Safety incidence was comparable between the 2 arms. In the TTFields/TMZ arm, 30% suffered from skin irritation versus 52% in the entire study population. No TTFields-related serious adverse events were reported. The median progression-free survival (PFS) in the TTFields/TMZ arm was 6.2 months (95% CI 4.2-12.2) versus 4.2 (95% CI 1.9-11.2) with TMZ alone (p = 0.67). Median overall survival was 27.2 months (95% CI 21-NA) with TTFields/TMZ versus 15.2 months (95% CI 7.5-24.1; HR 0.27, p = 0.01) with TMZ alone. CONCLUSION: Median OS and 1- and 2-year survival rates were higher with TTFields/TMZ and similar to the entire EF-14 population. About 30% of patients reported skin irritation, a lower rate than seen in the entire EF-14 population. These results demonstrate the efficacy and safety of TTFields in Korean newly diagnosed glioblastoma patients. CLINICAL TRIALS: Clinicaltrials.gov Identifier: NCT00916409. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | JOURNAL OF NEURO-ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학교실) | - |
dc.contributor.googleauthor | Chae-Yong Kim | - |
dc.contributor.googleauthor | Sun Ha Paek | - |
dc.contributor.googleauthor | Do-hyun Nam | - |
dc.contributor.googleauthor | Jong-Hee Chang | - |
dc.contributor.googleauthor | Yong-Kil Hong | - |
dc.contributor.googleauthor | Jeong Hoon Kim | - |
dc.contributor.googleauthor | Oh Lyong Kim | - |
dc.contributor.googleauthor | Se-Hyuk Kim | - |
dc.identifier.doi | 10.1007/s11060-019-03361-2 | - |
dc.contributor.localId | A03470 | - |
dc.relation.journalcode | J01629 | - |
dc.identifier.eissn | 1573-7373 | - |
dc.identifier.pmid | 32020470 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs11060-019-03361-2 | - |
dc.subject.keyword | Glioblastoma | - |
dc.subject.keyword | Korean GBM patients | - |
dc.subject.keyword | Tumor treating fields | - |
dc.contributor.alternativeName | Chang, Jong Hee | - |
dc.contributor.affiliatedAuthor | 장종희 | - |
dc.citation.volume | 146 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 399 | - |
dc.citation.endPage | 406 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEURO-ONCOLOGY, Vol.146(3) : 399-406, 2020 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.